6:15 PM - 7:15 PM
[II-JCKP1-04] Efficacy of a Special 6-Dose Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease in Subtropical Areas
Objective: Palivizumab prophylaxis for respiratory syncytial virus (RSV) infection in patients with hemodynamically significant congenital heart disease (hsCHD) has been proven to be effective in RSV seasons in Western countries. To study the efficacy of a novel palivizumab prophylaxis protocol for hsCHD in subtropical areas without clear RSV seasonality.
Method: The Taiwan National Health Insurance has provided reimbursement for palivizumab prophylaxis with a special 6-dose monthly protocol for patients with hsCHD. We performed a study to assess the trend of RSV infection in patients .
Results: Totally, 1646 patients were enrolled: 763 in the study group and 883 in the control group. Cyanotic CHD was observed in 41.6% of the patients. After a mean of 3.9 doses of palivizumab injection, the RSV hospitalization rates and hospitalization days decreased by 50% and 54%, respectively, in the study group compared with the control group (P = .013 and .025, respectively), and these values decreased further by 68.7% and 70% (P < .001 and .003), respectively. The RSV hospitalization rates decreased from 4.4% in the pre-palivizumab period to 2% in the palivizumab period (P = .038). The efficacy of this protocol was prominent both in patients with cyanotic hsCHD and in those with acyanotic hsCHD. The main causes of RSV infection after the palivizumab period were noncompliance and a delayed diagnosis of CHD.
Conclusions: Palivizumab prophylaxis through the novel 6-dose monthly protocol for patients with hsCHD is effective in reducing RSV-related hospitalization, with less doses and cost.
Method: The Taiwan National Health Insurance has provided reimbursement for palivizumab prophylaxis with a special 6-dose monthly protocol for patients with hsCHD. We performed a study to assess the trend of RSV infection in patients .
Results: Totally, 1646 patients were enrolled: 763 in the study group and 883 in the control group. Cyanotic CHD was observed in 41.6% of the patients. After a mean of 3.9 doses of palivizumab injection, the RSV hospitalization rates and hospitalization days decreased by 50% and 54%, respectively, in the study group compared with the control group (P = .013 and .025, respectively), and these values decreased further by 68.7% and 70% (P < .001 and .003), respectively. The RSV hospitalization rates decreased from 4.4% in the pre-palivizumab period to 2% in the palivizumab period (P = .038). The efficacy of this protocol was prominent both in patients with cyanotic hsCHD and in those with acyanotic hsCHD. The main causes of RSV infection after the palivizumab period were noncompliance and a delayed diagnosis of CHD.
Conclusions: Palivizumab prophylaxis through the novel 6-dose monthly protocol for patients with hsCHD is effective in reducing RSV-related hospitalization, with less doses and cost.